alpha1-ADRENERGIC RECEPTOR SUBTYPES IN HUMAN DETRUSOR
- 1 September 1998
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 160, 937-943
- https://doi.org/10.1097/00005392-199809010-00092
Abstract
To identify and quantitate alpha1-adrenergic receptor (alpha1AR) subtype expression in human detrusor. Initial studies to determine alpha1AR expression in human detrusor were performed using saturation binding with [125I]HEAT. Once the presence of alpha1ARs was documented, subtype (alpha1a, alpha1b, alpha1d) expression at the mRNA level (and comparison with rat) was determined with RNase protection assays (human detrusor) and RT-PCR (human detrusor, rat whole bladder). Competition binding analysis with the alpha1dAR-selective ligand BMY7378 was used to measure alpha1AR subtype expression at a protein level in human detrusor. Alpha1AR expression in human detrusor was low but reproducible (6.3 +/- 1.0 fmol./mg. total protein). RNase protection assays performed on total RNA extracted from human detrusor revealed the following alpha1AR subtype expression: alpha1d (66%) > alpha1a (34%), and no alpha1b. RT-PCR confirmed alpha1AR subtype mRNA distribution in human detrusor with alpha1d (approximately 60-70%) > alpha1a (approximately 30-40%), and a lack of alpha1b mRNA. Rat whole bladder expressed different alpha1AR subtype mRNA than human detrusor, with alpha1a approximately alpha1b approximately alpha1d. The presence of alpha1d > alpha1a expression in human detrusor was confirmed at a protein level by competition analysis utilizing BMY7378 which revealed a two-site fit, with Ki and high affinity binding (66%) consistent with the alpha1dAR subtype. Human detrusor contained two alpha1AR subtypes (alpha1d > alpha1a), a finding that is different from rat, another commonly used animal model. Since non-subtype selective alpha1AR antagonists ameliorate irritative bladder symptoms (in men and women with/without outlet obstruction), and Rec 15/2739 (alpha1a selective antagonist) does not improve symptom scores in BPH, our findings suggest bladder alpha1dARs may provide a potentially novel mechanism underlying these therapeutic benefits.Keywords
This publication has 24 references indexed in Scilit:
- Prospective study comparing hyoscyamine, doxazosin, and combination therapy for the treatment of urgency and frequency in womenNeurourology and Urodynamics, 1998
- Pharmacological pleiotropism of the human recombinant α1A‐adrenoceptor: implications for α1‐adrenoceptor classificationBritish Journal of Pharmacology, 1997
- Pharmacological characterization of α1‐adrenoceptor subtypes in the human prostate: functional and binding studiesBritish Journal of Urology, 1994
- Identification, Quantification, and Localization of mRNA for Three Distinct Alpha1Adrenergic Receptor Subtypes in Human ProstateJournal of Urology, 1993
- A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic HyperplasiaJournal of Urology, 1992
- The Relative Proportion of Stromal and Epithelial Hyperplasia is Related to the Development of Symptomatic Benign Prostate HyperplasiaJournal of Urology, 1992
- Effect of Bladder Outlet Obstruction on Micturition Reflex Pathways in the RatJournal of Urology, 1988
- Use of an α1-Blocker, YM-12617, in Micturition DifficultyUrologia Internationalis, 1987
- α-Adrenergic Blockade in the Diagnosis of Detrusor Instability Secondary to Infravesical ObstructionUrologia Internationalis, 1984
- Adrenergic and Cholinergic Receptors in the Human Prostate, Prostatic Capsule and Bladder NeckBritish Journal of Urology, 1975